First multicenter trial; CAR T-cell immunotherapy effective for lymphoma

(American Society of Hematology) A late-breaking abstract being presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego demonstrates that chimeric antigen receptor (CAR) T-cell therapy is a promising option for treating refractory non-Hodgkin lymphoma and practical to implement in a variety of real-world clinical settings.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news